Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy

Mise à jour : Il y a 5 ans
Référence : NCT01562821

Femme et Homme

Extrait

This trial is conducted in Asia. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.


Critère d'inclusion

  • Acquired Bleeding Disorder ,Cirrhosis

Liens